Moderna, Inc. (NASDAQ:MRNA – Get Free Report)’s share price reached a new 52-week low on Monday after an insider sold shares in the company. The company traded as low as $93.75 and last traded at $93.75, with a volume of 179556 shares changing hands. The stock had previously closed at $98.30.
Specifically, President Stephen Hoge sold 247 shares of Moderna stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $102.53, for a total transaction of $25,324.91. Following the sale, the president now directly owns 1,602,579 shares in the company, valued at approximately $164,312,424.87. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Moderna news, President Stephen Hoge sold 247 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $102.53, for a total value of $25,324.91. Following the transaction, the president now directly owns 1,602,579 shares in the company, valued at $164,312,424.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Shannon Thyme Klinger sold 557 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $107.22, for a total value of $59,721.54. Following the sale, the insider now owns 7,215 shares in the company, valued at approximately $773,592.30. The disclosure for this sale can be found here. Insiders have sold 204,912 shares of company stock worth $22,420,343 over the last 90 days. Corporate insiders own 15.70% of the company’s stock.
Wall Street Analysts Forecast Growth
MRNA has been the subject of several research analyst reports. TD Cowen cut shares of Moderna from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $145.00 to $125.00 in a research report on Friday, August 4th. Bank of America lowered their price objective on Moderna from $175.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, August 4th. HSBC assumed coverage on shares of Moderna in a research note on Friday, July 14th. They issued a “reduce” rating and a $97.00 target price on the stock. Royal Bank of Canada cut their price target on Moderna from $200.00 to $190.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Finally, Deutsche Bank Aktiengesellschaft downgraded Moderna from a “buy” rating to a “hold” rating and dropped their price objective for the company from $200.00 to $125.00 in a report on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $147.25.
Moderna Trading Down 6.5 %
The company has a market cap of $34.99 billion, a P/E ratio of 33.93 and a beta of 1.65. The company has a current ratio of 3.39, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $105.41 and a 200-day moving average price of $121.25.
Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($3.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.84) by $0.22. The firm had revenue of $344.00 million for the quarter, compared to analyst estimates of $307.67 million. Moderna had a net margin of 11.33% and a return on equity of 6.62%. The company’s quarterly revenue was down 92.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.24 earnings per share. Analysts forecast that Moderna, Inc. will post -4.32 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Moderna
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich raised its stake in Moderna by 98,101.2% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 142,396,614 shares of the company’s stock valued at $17,301,189,000 after acquiring an additional 142,251,609 shares during the period. Baillie Gifford & Co. raised its position in shares of Moderna by 3.7% in the first quarter. Baillie Gifford & Co. now owns 46,466,171 shares of the company’s stock valued at $7,136,275,000 after purchasing an additional 1,679,425 shares during the period. State Street Corp lifted its stake in shares of Moderna by 1.1% during the 2nd quarter. State Street Corp now owns 14,227,227 shares of the company’s stock worth $1,728,608,000 after buying an additional 150,872 shares during the last quarter. Geode Capital Management LLC grew its stake in Moderna by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 6,302,497 shares of the company’s stock valued at $763,754,000 after buying an additional 57,540 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Moderna by 0.4% in the 1st quarter. Wellington Management Group LLP now owns 4,292,235 shares of the company’s stock valued at $659,201,000 after buying an additional 15,271 shares during the last quarter. Institutional investors own 64.51% of the company’s stock.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
See Also
- Five stocks we like better than Moderna
- Business Services Stocks Investing
- Warren Buffett Stocks: What’s in Warren Buffett’s Portfolio?
- Breakout Stocks: What They Are and How to Identify Them
- Snack Maker Mondelez Int’l Is Down but Not Out
- How and Why to Invest in Oil Stocks
- Costco, Dollar General, Target Up As Market Turns Defensive
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
